Generic Industry Wants More Guidance On Demonstrating Equivalence Of Drug-Device Combinations
Executive Summary
Firms want US FDA to better address how generic drug manufacturers can demonstrate similarity to innovator drug-device combination products.
You may also be interested in...
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
The latest drug development news and highlights from our US FDA Performance Tracker.